Our findings suggest that GLP-1 therapy holds real promise. While a randomized trial is still needed, the fact that many patients with IIH already qualify for GLP-1s due to diabetes or obesity means ...

Eli Lilly this week announced it has submitted applications to US and European regulatory agencies for nasal glucagon, which, if approved, could shave minutes and stress from the current method for ...

Please provide your email address to receive an email when new articles are posted on . Fewer people with diabetes filled glucagon prescriptions in 2021 compared with 2011, though increases were seen ...

Glucagon increases the production of glucose by increasing glycogenolysis and gluconeogenesis in the liver, and by reducing glycogenesis and glycolysis. The release of glucagon in response to food ...

Xeris Pharmaceuticals has teamed up with the American Diabetes Association (ADA) to raise awareness of the importance of prescribing glucagon, positioning the partners to address a fundamental barrier ...

The US Food and Drug Administration has approved the first-ever generic glucagon injection kit for the treatment of severe hypoglycemia in patients with diabetes and as a diagnostic aid. The FDA ...

The glucagon-like peptide 1 (GLP-1) market is poised for growth due to rising diabetes and obesity rates, expanded therapy options, and a focus on personalized medicine. Innovations in oral GLP-1 ...

SAN DIEGO -- A novel formulation of glucagon administered as a dry mist nasal spray showed real-world effectiveness when administered to treat moderate or severe hypoglycemia in adults with type 1 ...

Glucagon prescriptions for severe hypoglycemia in Medicaid initially decreased from 2012 to 2018 but increased between 2019 and 2023 following the introduction of newer products. Glucagon ...